AIZN vs REGN · $9.38B cap vs P/E 14, rev $4.29B
Assurant, Inc. 5.25% Subordinat (AIZN) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Assurant, Inc. 5.25% Subordinat (AIZN) common stock listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
AIZN does not have a complete income-statement cache yet.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
AIZN currently screens at market cap $9.38B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the AIZN and REGN stock pages for the full models.
Not investment advice.